This page was automatically translated and accurateness of translation is not guaranteed. Please refer to the English version for a source text.

3D ECG for Detection of Cardiomyopathy

3D ECG for Detection of Cardiomyopathy in Heart Failure

Sponsors

Commanditaire principal: University Hospital, Essen

La source University Hospital, Essen
Bref résumé

There is existing data in the literature that suggests an additional predictive value of three dimensional ECG with respect to the presence of electrical abnormalities and for an existing cardiac disease. Especially regarding patients who suffered from a myocardial infarction in the past (post MI patients), evidence has been provided for a potential association of 3D repolarisation abnormalities and incidence of sudden cardiac death (SCD). In addition, there is some vague evidence of so called 3D ECG and prediction of coronary artery disease. This 3D ECG device is using the technology of 3D ECG vector loops and is assessing the variability of these ECG vector loops in the 3-dimensional space. Based on these data, the parameters of 3D ECG are suggested to carry certain value to predict or to identify individuals already suffering from a cardiac disease or being at risk experiencing a cardiac event in the future. In this context we performed a preliminary study with 3D-ECG device in healthy volunteers evaluating the robustness of this method with respect to reproducibility, intra- and intra-observer variability which could be confirmed. We thus postulate that the 3D ECG technology might bear the potential to serve as a sufficient screening method for diagnosing cardiomyopathy in patients with an unknown heart failure etiology.

Situation globale Recruiting
Date de début 2021-03-14
Date d'achèvement 2021-10-14
Date d'achèvement principale 2021-09-14
Type d'étude Observational
Résultat primaire
Mesure Plage de temps
Cardiomyopathy Within 24 hours
Inscription 175
État
Intervention

Type d'intervention: Diagnostic Test

Nom de l'intervention: 3D-ECG

La description: Patient recieves 3D-ECG Assessement

Étiquette du groupe d'armements: Patient recieving 3D-ECG-Evaluation

Admissibilité

Méthode d'échantillonnage:

Probability Sample

Critères:

Inclusion Criteria: - Age >18 Years - Established diagnosis heart failure and suggested cardiomyopathy Exclusion Criteria: - Patients unable to sign informed consent - Pacemaker-stimulated ECG

Le sexe:

All

Âge minimum:

18 Years

Âge maximum:

N/A

Volontaires en santé:

No

Officiel général
Nom de famille Rôle Affiliation
Reza Wakili, Prof. Principal Investigator University Hospital, Essen
Contact général

Nom de famille: Reza Wakili, Prof.

Téléphone: 00492017234802

Email: reza.wakili@uk-essen.de

Emplacement
Établissement: Statut: Contact: Sauvegarde de contact: West-German Heart and Vascular Center Essen, University Hospital Essen Reza Wakili, Prof. Dr. 0201 723 4802 reza.wakili@uk-essen.de
Pays d'implantation

Germany

Date de vérification

2021-04-01

Partie responsable

Type: Sponsor

A un accès étendu No
Parcourir l'état
Groupe d'armes

Étiquette: Patient recieving 3D-ECG-Evaluation

Données patient No
Informations sur la conception de l'étude

Modèle d'observation: Cohort

Perspective temporelle: Prospective

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

analytics

Essais cliniques sur Heart Failure

3
S'abonner